186 related articles for article (PubMed ID: 37045600)
1. Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
He J; Qi J; Han H; Xu X; Li X; Song X; Han Y
Expert Rev Hematol; 2023 May; 16(5):377-385. PubMed ID: 37045600
[TBL] [Abstract][Full Text] [Related]
2. Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
Djulbegovic M; Tong J; Xu A; Yang J; Chen Y; Cuker A; Pishko AM
Blood Adv; 2023 May; 7(10):2132-2142. PubMed ID: 36053773
[TBL] [Abstract][Full Text] [Related]
3. Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience.
Tse B; Buchholz M; Pavenski K
Platelets; 2023 Dec; 34(1):2157807. PubMed ID: 36636834
[TBL] [Abstract][Full Text] [Related]
4. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
Picod A; Veyradier A; Coppo P
J Thromb Haemost; 2021 Jan; 19(1):58-67. PubMed ID: 33236389
[TBL] [Abstract][Full Text] [Related]
5. Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.
Seguí IG; Mingot Castellano ME; Izquierdo CP; de la Rubia J
Expert Rev Hematol; 2024; 17(1-3):9-25. PubMed ID: 38353182
[TBL] [Abstract][Full Text] [Related]
6. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
[TBL] [Abstract][Full Text] [Related]
8. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
le Besnerais M; Veyradier A; Benhamou Y; Coppo P
Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
[No Abstract] [Full Text] [Related]
9. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
Völker LA; Kaufeld J; Balduin G; Merkel L; Kühne L; Eichenauer DA; Osterholt T; Hägele H; Kann M; Grundmann F; Kolbrink B; Schulte K; Gäckler A; Kribben A; Boss K; Potthoff SA; Rump LC; Schmidt T; Mühlfeld AS; Schulmann K; Hermann M; Gaedeke J; Sauerland K; Bramstedt J; Hinkel UP; Miesbach W; Bauer F; Westhoff TH; Bruck H; Buxhofer-Ausch V; Müller TJ; Wendt R; Harth A; Schreiber A; Seelow E; Tölle M; Gohlisch C; Bieringer M; Geuther G; Jabs WJ; Fischereder M; von Bergwelt-Baildon A; Schönermarck U; Knoebl P; Menne J; Brinkkoetter PT;
J Thromb Haemost; 2023 Mar; 21(3):559-572. PubMed ID: 36696206
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
Peng JY; Wang SY; Chen MQ; Liu CX; Zhao YT; Xu TS; Wu QL
Blood Coagul Fibrinolysis; 2024 Jun; ():. PubMed ID: 38874905
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.
Knoebl P; Cataland S; Peyvandi F; Coppo P; Scully M; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Minkue Mi Edou J; De Winter H; Callewaert F
J Thromb Haemost; 2020 Feb; 18(2):479-484. PubMed ID: 31691462
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.
Izquierdo CP; Mingot-Castellano ME; Fuentes AEK; García-Arroba Peinado J; Cid J; Jimenez MM; Valcarcel D; Gómez-Seguí I; de la Rubia J; Martin P; Goterris R; Hernández L; Tallón I; Varea S; Fernández M; García-Muñoz N; Vara M; Zarzoso MF; García-Candel F; Paciello ML; García-García I; Zalba S; Campuzano V; Gala JM; Estévez JV; Jiménez GM; López Lorenzo JL; Arias EG; Freiría C; Solé M; Ávila Idrovo LF; Hernández Castellet JC; Cruz N; Lavilla E; Pérez-Montaña A; Atucha JA; Moreno Beltrán ME; Moreno Macías JR; Salinas R; Del Rio-Garma J
Blood Adv; 2022 Dec; 6(24):6219-6227. PubMed ID: 35930694
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study.
Arnaud A; Schilsky S; Lucia J; Maia M; Laredo F; Marques AP; Okada H; Roberts AW
Clin Appl Thromb Hemost; 2024; 30():10760296241241525. PubMed ID: 38523315
[TBL] [Abstract][Full Text] [Related]
14. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
[TBL] [Abstract][Full Text] [Related]
15. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
Poullin P; Bornet C; Veyradier A; Coppo P
Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study.
Miyakawa Y; Imada K; Ichikawa S; Uchiyama H; Ueda Y; Yonezawa A; Fujitani S; Ogawa Y; Matsushita T; Asakura H; Nishio K; Suzuki K; Hashimoto Y; Murakami H; Tahara S; Tanaka T; Matsumoto M
Int J Hematol; 2023 Mar; 117(3):366-377. PubMed ID: 36427162
[TBL] [Abstract][Full Text] [Related]
17. Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange.
Kühne L; Knoebl P; Eller K; Thaler J; Sperr WR; Gleixner KV; Osterholt T; Kaufeld JK; Menne J; Buxhofer-Ausch V; Mühlfeld AS; Seelow E; Schreiber A; Todorova P; Cukoski S; Jabs WJ; Özcan F; Gäckler A; Schönfelder K; Seibert FS; Westhoff TH; Schwenger V; Eichenauer DA; Völker L; Brinkkoetter P
Blood; 2024 Jun; ():. PubMed ID: 38838300
[TBL] [Abstract][Full Text] [Related]
18. Caplacizumab as rescue therapy in refractory TTP involving neurologic features.
Tran MH; Lee LX; Cao Y; Vu L; Pakbaz Z
Transfus Apher Sci; 2023 Jun; 62(3):103656. PubMed ID: 36863912
[TBL] [Abstract][Full Text] [Related]
19. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
[TBL] [Abstract][Full Text] [Related]
20. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
Coppo P; Bubenheim M; Azoulay E; Galicier L; Malot S; Bigé N; Poullin P; Provôt F; Martis N; Presne C; Moranne O; Benainous R; Dossier A; Seguin A; Hié M; Wynckel A; Delmas Y; Augusto JF; Perez P; Rieu V; Barbet C; Lhote F; Ulrich M; Rumpler AC; de Witte S; Krummel T; Veyradier A; Benhamou Y
Blood; 2021 Feb; 137(6):733-742. PubMed ID: 33150928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
